Impairment of the Schistosoma mansoni-specific immune responses elicited by treatment with praziquantel in Ugandans with HIV-1 coinfection

J Infect Dis. 2004 Aug 1;190(3):613-8. doi: 10.1086/422396. Epub 2004 Jul 1.

Abstract

We show that Ugandan adults coinfected with Schistosoma mansoni and human immunodeficiency virus type 1 (HIV-1) are able to mount S. mansoni-specific immune responses but that few such responses increase after treatment with praziquantel (PZQ). Levels of soluble worm antigen (SWA)-specific immunoglobulin (Ig) G1, IgG2, IgG3, IgG4, interleukin (IL)-4, and IL-5 increased significantly in HIV-negative participants after treatment with PZQ, whereas most soluble egg antigen-specific antibody responses and levels of interferon- gamma were unaltered. Only levels of SWA-specific IL-5 increased in HIV-1-coinfected participants after treatment. These deficiencies in immune responses may account for the previously reported increased susceptibility to infection and reinfection with S. mansoni in individuals coinfected with HIV-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Anthelmintics / therapeutic use*
  • Antibodies, Helminth / blood*
  • Antigens, Helminth / immunology
  • Cytokines / metabolism*
  • HIV Infections / complications*
  • HIV-1 / immunology
  • Humans
  • Male
  • Praziquantel / therapeutic use*
  • Schistosoma mansoni / immunology
  • Schistosomiasis mansoni / complications
  • Schistosomiasis mansoni / drug therapy
  • Schistosomiasis mansoni / immunology*
  • Uganda

Substances

  • Anthelmintics
  • Antibodies, Helminth
  • Antigens, Helminth
  • Cytokines
  • Praziquantel